Please assess the completion status of the following clinical trial:

Trial Title: QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~1. Able to provide a signed, executed written informed consent~2. Healthy non-smoking adult volunteers: Male or Female subjects 18 to 45 years old~3. Female subjects who are practicing adequate contraception (see section 4.4) or who are sterile~4. No known cardiac disease~5. Normal hemoglobin values~6. Normal or not clinically significant 12-lead Electrocardiogram~   * Heart rate ≥ 40 and ≤ 100 at Visit 1 vital signs assessment (resting)~  * Subjects with QTcF interval duration \<430 msec for males and \<450 msec for females obtained from the ECG recorder's measurements on the screening ECG taken after at least 5 minutes of quiet rest in supine position~7. Demonstrated ability to properly use the Tempo® Inhaler~8. Subject has not donated blood in the last 56 days~Exclusion Criteria:~1. Contraindication to dihydroergotamine mesylate (DHE)~2. History of hemiplegic or basilar migraine~3. Family history of long QT syndrome~4. Participation in another investigational trial during the 30 days prior to Visit 1

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Treatment A, then Treatment B, then Treatment C (Type: OTHER): There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing.
- Treatment A, then Treatment C, then Treatment B (Type: OTHER): There was 48 hour wash-out between treatment visits. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 2.~Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing.
- Treatment B, then Treatment A, then Treatment C (Type: OTHER): There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment C = inhaler placebo and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing.
- Treatment B, then Treatment C, then Treatment A (Type: OTHER): There was 48 hour wash-out between treatment visits. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 2. Treatment C = inhaler placebo and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing.
- Treatment C, then Treatment A, then Treatment B (Type: OTHER): There was 48 hour wash-out between treatment visits. Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 3.~Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 4. Tablets were orally administered after oral inhalation dosing.
- Treatment C, then Treatment B, then Treatment A (Type: OTHER): There was 48 hour wash-out between treatment visits.~Treatment C = inhaler placebo and placebo capsules at Visit 2. Treatment B = MAP0004 3.0mg (via inhalation) and placebo capsules at Visit 3. Treatment A = inhaler placebo and moxifloxacin 400mg encapsulated tablet at Visit 4.~Tablets were orally administered after oral inhalation dosing.

Based on this trial design, predict the completion outcome and termination type (if applicable).